UGT2B17 gene deletion associated with an increase in bone mineral density similar to the effect of hormone replacement in postmenopausal women

[1] Turgeon D(2001)Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members Endocrinology 142 778-787

[2] Carrier JS(2001)Sex steroids and bone Physiol Rev 81 419-447

[3] Levesque E(2006)Common deletion polymorphisms in the human genome Nat Genet 38 86-92

[4] Hum DW(2008)Adaptive evolution of UGT2B17 copy-number variation Am J Hum Genet 83 337-346

[5] Belanger A(2008)Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation J Clin Endocrinol Metab 93 2500-2506

[6] Compston JE(2006)Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism J Clin Endocrinol Metab 91 687-693

[7] McCarroll SA(2007)The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case–control study in Caucasians Cancer Detect Prev 31 310-315

[8] Hadnott TN(2008)Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate Pharmacogenomics J 8 147-151

[9] Perry GH(2008)The UGT2B17 gene deletion is not associated with prostate cancer risk Prostate 68 571-575

[10] Xue Y(2006)Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men Cancer Epidemiol Biomark Prev 15 1473-1478

[1] Turgeon D(2001)Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members Endocrinology 142 778-787

[2] Carrier JS(2001)Sex steroids and bone Physiol Rev 81 419-447

[3] Levesque E(2006)Common deletion polymorphisms in the human genome Nat Genet 38 86-92

[4] Hum DW(2008)Adaptive evolution of UGT2B17 copy-number variation Am J Hum Genet 83 337-346

[5] Belanger A(2008)Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation J Clin Endocrinol Metab 93 2500-2506

[6] Compston JE(2006)Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism J Clin Endocrinol Metab 91 687-693

[7] McCarroll SA(2007)The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case–control study in Caucasians Cancer Detect Prev 31 310-315

[8] Hadnott TN(2008)Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate Pharmacogenomics J 8 147-151

[9] Perry GH(2008)The UGT2B17 gene deletion is not associated with prostate cancer risk Prostate 68 571-575

[10] Xue Y(2006)Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men Cancer Epidemiol Biomark Prev 15 1473-1478